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Design: Cross-sectional analysis of weighted data from a probability sample of HIV-
infected adults receiving outpatient medical care. The facility and patient response rates
were 76 and 51%, respectively.
Methods: We analysed 2009 interview and medical record data. Sexual behaviours
were self-reported in the past 12 months. Viral suppression was defined as all viral load
measurements in the medical record during the past 12 months less than 200 copies/ml.
Results: An estimated 98022 (24%) HIV-infected adults engaged in unprotected
vaginal or anal sex; 50 953 (12%) engaged in unprotected vaginal or anal sex with
at least one partner of negative or unknown HIV status; 23 933 (6%) did so while not
virally suppressed. Persons who were virally suppressed were less likely than persons
who were not suppressed to engage in vaginal or anal sex [prevalence ratio, 0.88; 95%
confidence interval (CI), 0.82–0.93]; unprotected vaginal or anal sex (prevalence ratio,
0.85; 95% CI, 0.73–0.98); and unprotected vaginal or anal sex with a partner of
negative or unknown HIV status (prevalence ratio, 0.79; 95% CI, 0.64–0.99).
Conclusion: The majority of HIV-infected adults receiving medical care in the U.S. did
not engage in sexual risk behaviours that have the potential to transmit HIV, and of the
12%who did, approximately half were not virally suppressed. Persons whowere virally
suppressed were less likely than persons who were not suppressed to engage in sexual
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1204 AIDS 2014, Vol 28 No 8IntroductionThe number of persons aged 13 years and older newly
infected with HIV in 2010 in the United States was
estimated to be 47 500, and 88% of all newHIV infections
were attributed to sexual transmission [1]. Recent
estimates suggest that approximately four transmissions
occur per 100 HIV-infected persons annually [2];
however, nationally representative data on sexual risk
behaviours have not been available since the late 1990s
[3]. Thus, national data on the sexual risk behaviour of
HIV-infected persons are needed to inform prevention
efforts to reduce sexual transmission of HIV and the
acquisition of other sexually transmitted infections (STIs).
Providing antiretroviral therapy (ART) improves indi-
vidual health outcomes and observational evidence and a
randomized clinical trial have demonstrated that taking
ART substantially reduces the risk of heterosexual HIV
transmission [4,5]. Although this finding has profound
implications for HIV prevention, access to ART does
not eliminate all the barriers that may interfere with
the elimination of HIV transmission, including delayed
diagnosis, lack of continuous care, suboptimal adherence,
drug resistance and subsequent increases in risky sexual
behaviour (i.e. risk compensation) [6–10]. Findings from
prior investigations of the association between ART
provision and increased sexual risk behaviour are mixed
[11–14]. Soon after effective therapy became widely
available in developed countries, evidence suggested a
resurgence of HIV and other STIs, especially syphilis,
among MSM [13,15]. Some data, including meta-
analyses, have indicated no increases in sexual risk
behaviour among persons who received ART or were
virally suppressed, but the prevalence of unprotected sex
was higher among HIV-infected adults who believed that
ART or viral suppression protects against transmission
[12,14].
In this report, we present data (overall and stratified by
viral suppression) to describe sexual risk behaviours in a
national sample of HIV-infected adults receiving medical
care in the United States. Given the increased probability
of HIV transmission when individuals are not virally
suppressed, we also assess the association between sexual
risk behaviour and viral suppression.Materials and methods
The Medical Monitoring Project (MMP) uses a three-
stage sampling design to obtain nationally representative,
annual cross-sectional samples of HIV-infected adults
receiving outpatient medical care for HIV [16]. For the
2009 data collection cycle, U.S. states and territories were
sampled, followed by outpatient facilities providing HIV
care, and finally by HIV-infected adults aged 18 years andpyright © Lippincott Williams & Wilkins. Unauthoolder who reported at least one medical care visit in a
participating facility during January–April 2009. For
state and territory samples, probability of selection
was proportionate to AIDS prevalence; for provider
samples, probability of selection was proportionate to
HIV-infected patient census. Data were collected via
face-to-face interviews and medical record abstractions
during June 2009–May 2010. All sampled states and
territories participated in MMP [California (including
Los Angeles County and San Francisco), Delaware,
Florida, Georgia, Illinois (including Chicago), Indiana,
Michigan, Mississippi, New Jersey, New York (including
New York City), North Carolina, Oregon, Pennsylvania
(including Philadelphia), Puerto Rico, Texas (including
Houston), Virginia, and Washington]. Of 603 sampled
facilities, 461 participated in MMP (facility response rate,
76%); of 9338 sampled persons, 51% (n¼ 4127) were
interviewed and had their medical records abstracted,
resulting in a combined facility-patient response rate of
39% [17]. Data were weighted on the basis of known
probabilities of selection at state or territory, facility and
patient levels [18]. In addition, using information
collected on all sampled facilities and 88% of sampled
patients, we conducted an analysis to compare respon-
dents and nonrespondents. Data were then weighted to
adjust for nonresponse by using predictors of response,
including facility size, facility type (public or private),
patient race and ethnicity, time since HIV diagnosis and
age group [18,19]. We analysed data on 4094 participants
whose diagnosis was made at least 12 months earlier and
weighted the data to represent 408 092 HIV-infected
adults in care in the United States during January–April
2009. The Centers for Disease Control and Prevention
(CDC) has determined that MMP is a public health
surveillance activity [20]. BecauseMMP is not considered
research, it is not subject to human subjects regulations
including federal institutional review board (IRB) [21].
Despite this designation, voluntary informed consent
was obtained from all participants who completed
an interview. Several participating states, territories and
facilities obtained local IRB approval to conduct MMP
and also obtained informed consent to abstract informa-
tion from patients’ medical records.
Measures
All measures reflect self-reported behaviours or experi-
ences in the 12 months before the interview unless
otherwise noted. Men were classified as MSM if they
reported oral or anal sex with other men, whether or not
they also reported sex with women. Men were classified
as men who have sex with women (MSW) if they
reported oral, anal or vaginal sex exclusively with women.
Women were classified as women who have sex with men
(WSM) if they reported oral, anal or vaginal sex with
men, whether or not they also reported sex with women.
Women were classified as women who have sex with
women (WSW) if they reported oral or vaginal sex
exclusively reported sex with women. Participants wererized reproduction of this article is prohibited.
Sexual risk behaviour and viral suppression Mattson et al. 1205considered transgender if their sex at birth did not
match their current sexual identity or if they self-
identified as transgender. Participants who reported no
anal, vaginal or oral sex in the past 12 months were
categorized according to self-reported sexual orientation.
Covariates obtained from interview data included
demographic characteristics (e.g. age, race/ethnicity,
education) and behaviours (e.g. number of sex partners,
self-reported syphilis, gonorrhoea, chlamydia, herpes,
genital warts or other sexually transmitted diseases, and
alcohol, stimulant, poppers, methamphetamines or any
other drug use before sex).
Viral load, the prescription of ART and HIV staging
data were abstracted from medical records. Because
sexual risk behaviours could have occurred at any
time during the 12-month period prior to the inter-
view, we defined durable viral suppression, hereafter
referred to as viral suppression, as an HIV-1 RNA
level that was documented as undetectable or less than
200 copies/ml at every measurement (minimum 1) in the
past 12 months.Copyright © Lippincott Williams & Wilkins. Unaut
Table 1. Sociodemographic and clinical characteristics of adults with HIV
United States, Medical Monitoring Project, 2009.
Characteristic
Totala (n¼4094) MSM (n
Weighted %
(95% CI)
Weig
(95
Age at the time of interview (years)
18–29 7 (6–8) 8 (6
30–39 17 (15–18) 16 (1
40–49 40 (38–42) 41 (3
50 36 (35–38) 35 (3
Race/ethnicity
Black, non-Hispanic 41 (33–49) 22 (1
White, non-Hispanic 35 (28–41) 54 (4
Hispanic 19 (14–24) 19 (1
Multiracial/other 5 (4–6) 5 (4
Education
<High school 23 (20–25) 9 (7
High school 27 (24–30) 22 (1
>High school 50 (46–55) 69 (6
At or below the poverty levelb 44 (40–48) 26 (2
Experienced homelessnessb 9 (8–10) 6 (5
In jail >24hb 6 (5–7) 3 (3
Continuous health insurance or coverageb 72 (67–76) 72 (6
HIV diagnosis >–5 years earlier 78 (76–80) 78 (7
Prescribed antiretroviral therapy 89 (88–91) 90 (8
>–3 viral load measurements
b 62 (60–65) 61 (5
All viral load measures in the
past year <200 copies/ml
59 (56–62) 63 (6
Clinical status
AIDS or CD4þ cell count
0–199cells/ml (nadir)
68 (66–70) 65 (6
No AIDS and CD4þ cell count
200–499 cells/ml (nadir)
25 (23–27) 28 (2
No AIDS and CD4þ cell count
500 cells/ml (nadir)
7 (6–8) 7(5
CI, confidence interval; MSM, men have sex with men; MSW, men who h
aExcludes persons who reported no sexual behaviour and did not report thei
transgender participants (n¼64) andwomenwho have sex with women (n¼
separate analysis.
bRefers to the 12 months before interview (June 2008–May 2009).Data analysis
We considered three separate measures of sexual
behaviour that took place in the past 12 months: vaginal
or anal sex; ‘unprotected vaginal or anal sex’during which
a condom was not used or was used inconsistently; and
unprotected vaginal or anal sex with a partner of negative
or unknownHIV status. For each outcome, we generated
weighted population estimates, weighted percentages and
95% confidence intervals (95% CIs) for all persons whose
HIV diagnosis had been made at least 12 months earlier
and separately for MSM, MSW and WSM. We used
modified Rao-Scott chi-square tests and 95%CIs to assess
sociodemographic, behavioural and clinical differences
among MSM, MSWand WSM [22,23]. To examine the
association between viral suppression and each measure of
sexual behaviour as a dependent variable, we calculated
crude prevalence ratios and 95% CIs by using logistic
regression with predicted marginal means [24]. Data were
weighted for nonresponse [18] and all analyses accounted
for the complex sample design and unequal selection
probabilities by using the survey procedures in SAS
9.3 [25] and SUDAAN 10.0.1 [26].horized reproduction of this article is prohibited.
diagnosis for at least 12 months and receiving medical care in the
¼1897) MSW (n¼1016) WSM (n¼1093) P for modified
Rao-Scott chi-
square test
hted %
% CI)
Weighted %
(95% CI)
Weighted %
(95% CI)
–9) 4 (2–5) 9 (7–11) <0.001
4–18) 12 (10–15) 21 (18–24)
9–44) 39 (36–42) 39 (35–43)
3–38) 45 (42–49) 31 (28–34)
6–28) 56 (46–67) 62 (54–70) <0.001
8–61) 17 (11–23) 18 (14–22)
6–22) 22 (13–32) 17 (10–24)
–6) 5 (3–7) 3 (2–5)
–11) 36 (33–40) 34 (31–38) <0.001
9–24) 34 (31–37) 30 (26–34)
5–74) 30 (25–34) 36 (32–40)
3–29) 58 (54–62) 62 (57–67) <0.001
–8) 14 (11–16) 8 (7–10) <0.001
–4) 11 (8–14) 5 (4–7) <0.001
6–78) 71 (65–76) 74 (69–79) 0.238
5–80) 77 (74–81) 80 (77–83) 0.444
9–92) 91 (89–93) 86 (83–89) 0.006
9–64) 66 (62–71) 60 (56–64) 0.236
0–66) 58 (54–62) 53 (49–57) <0.001
3–68) 76 (73–80) 65 (62–68) <0.001
5–31) 18 (15–21) 27 (24–29)
–9) 5 (4–7) 8 (6–10)
ave sex with women; WSM, women who have sex with men.
r sexual orientation as heterosexual, homosexual or bisexual. Includes
26) because sample sizes were too small to provide valid estimates for
Co
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Among HIV-infected persons in care whose diagnosis
occurred at least 12 months earlier, 46% (95% CI, 42–51)
were MSM, 24% (95% CI, 21–26) were MSW, 27%
(95% CI, 23–30) were WSM, 2% (95% CI, 1–2) were
transgender and less than 1% (95% CI, 0.4–1.1) were
WSW. Approximately 40% of persons were aged 40–
49 years, 41% were non-Hispanic blacks and 50% had
more than a high school education (Table 1). In the past
12 months, 89% had been prescribed ART, and 59%
had been virally suppressed at all measurements; 68% had
ever received an AIDS diagnosis. We found statistically
significant differences in the sociodemographic and
clinical characteristics of MSM, MSWand WSM except
for continuous healthcare coverage in the past 12 months,
length of time since HIV diagnosis and number of viral
load measurements in the past 12 months.
Overall, 62% reported oral, anal or vaginal sex with
one or more partners in the past 12 months; 13% reported
an STI; and 56% reported not having been tested for STIs.
In addition, 24% drank alcohol and 11% used drugs
before or during sex (Table 2). MSM were significantly
more likely than MSWorWSM to have had two or more
partners and to have drunk alcohol or used drugs
before or during sex; MSM, compared with MSW,
were significantly more likely to report an STI. MSW,
compared with MSM or WSM, were significantly more
likely to report that they had not been tested for an STI;
compared with WSM, MSW were more likely to have
used noninjection drugs and report exchanging sex forpyright © Lippincott Williams & Wilkins. Unautho
Table 2. Sexual and drug-use behaviours of men who have sex with men,
with HIV diagnosis for at least 12 months receiving medical care in the
Characteristicsa
Totalb (n¼4094) MSM (n¼18
Weighted %
(95% CI)
Weighted %
(95% CI)
Number of sex partners
None 38 (35–40) 31 (28–34
1 38 (36–41) 31 (28–33
 2 24 (21–27) 39 (34–42
Self-reported sexually transmitted infection
Yes 13 (11–15) 16 (13–19
No 31 (29–33) 32 (29–34
Not tested 56 (54–58) 52 (49–56
Used noninjection drugs 27 (26–29) 35 (32–37
Drank alcohol before/during sex 24 (22–26) 32 (29–35
Drug use before or during sex
Any drug 11 (10–13) 16 (14–18
Stimulants 5 (4–6) 7 (6–9)
Poppers 3 (2–4) 6 (4–7)
Methamphetamines 2 (2–3) 5 (3–6)
Exchanged sex for money/goods 4 (3–4) 3 (2–4)
CI, confidence interval; MSM, men who have sex with men; MSW, men who
coefficient of variation was >0.30 (sample size too small to produce valid
aRefers to the 12 months before interview (June 2008–May 2009)
bExcludes persons who reported no sexual behaviour and did not report thei
transgender participants (n¼64) andwomenwho have sexwith women (n¼
separate analysis.money or goods. WSM, compared with MSM, were
significantly more likely to report no sex partners, and
they were more likely than MSW to report an STI.
Viral suppression and sexual risk behaviour
Of the estimated 408 092 (95% CI, 366 524–449 660)
HIV-infected adults diagnosed for at least 12 months
and receiving care, 224 112 (95% CI, 203 005–245 219)
(56%) engaged in vaginal or anal sex; 98 022 (95% CI,
83 019–113 025) (24%) engaged in unprotected vaginal
or anal sex; 50 953 (95% CI, 44 791–57 115) (12%)
engaged in unprotected vaginal or anal sex with a partner
of negative or unknown HIV status (Fig. 1). Notably,
23 933 (95% CI, 20 155–27 712) (6%) engaged in
unprotected vaginal or anal sex with a partner of negative
or unknown HIV status while not virally suppressed.
In other words, of those who engaged in unprotected
vaginal or anal sex with a partner of negative or unknown
HIV status, approximately half were not virally suppressed.
As shown in a supplemental table, http://links.lww.com/
QAD/A510, MSM were significantly more likely than
MSWor WSM to engage in unprotected sex, and WSM
were significantly more likely than MSW to engage
in unprotected sex (available at www.AIDSonline.com).
In addition, WSM were significantly more likely than
MSW to engage in unprotected sex with a partner of
negative or unknown HIV status. Approximately 51%, or
an estimated 3212 (95% CI, 1675–4749) transgender
persons engaged in vaginal or anal sex, and 65%, or an
estimated 1986 (95% CI, 967–3005) WSW reported sex
with a woman in the past 12 months (data not shown).rized reproduction of this article is prohibited.
men who have sex with women and women who have sex with men
United States, Medical Monitoring Project, 2009.
97) MSW (n¼1016) WSM (n¼1093) P for modified
Rao-Scott chi-
square test
Weighted %
(95% CI)
Weighted %
(95% CI)
) 43 (38–47) 46 (43–48) <0.001
) 44 (41–48) 47 (44–50)
) 13 (11–15) 8 (5–10)
) 6 (5–8) 12 (8–16) <0.001
) 26 (23–30) 35 (31–39)
) 68 (64–72) 53 (49–57)
) 24 (21–27) 17 (15–19) <0.001
) 19 (16–32) 15 (13–18) <0.001
) 7 (5–9) 7 (5–8) <0.001
2 (1–3) 3 (2–4) <0.001
–— –—
–— –—
5 (3–7) 2 (1–3) 0.009
have sex with women; WSM, women who have sex with men; dash,
estimates).
r sexual orientation as heterosexual, homosexual or bisexual. Includes
26) because sample sizes were too small to provide valid estimates for
Sexual risk behaviour and viral suppression Mattson et al. 1207
Vaginal or anal sex, suppressed          Unprotected sex, suppressed     Unprotected sex with a negative or
unknown status partner, suppressed 
Vaginal or anal sex, not suppressed    Unprotected sex, not suppressed      Unprotected sex with a negative or
unknown status partner, not suppressed  
25%
11% 6%
24%
13%
6%
25%
6% 4%
28%
11% 7%
56%
24%
12%
58%
30%
13%
56%
14%
9%
53%
22%
15%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Total (N = 4006) MSMb (N = 1897) MSWc (N = 1016) WSMd (N = 1093)
Fig. 1. Prevalence of vaginal or anal sex and viral suppressiona among adults with HIV diagnosis for at least 12 months and
receiving medical care in the United States, by sexual behaviour, Medical Monitoring Project, 2009. There were no statistically
significant differences between MSM, MSW and WSM in engaging in anal or vaginal sex. More MSM (30%) had unprotected sex
than MSW (14%) and WSM (22%). More WSM (22%) had unprotected sex than MSW (14%). More WSM (15%) had unprotected
sex with an HIV-negative or unknown stats partner than MSW (9%). aAll viral load measurements in the 12 months before
interview undetectable or <200 copies/ml; bMSM, men who have sex with men; cMSW, men who have sex with women; dWSM,
women who have sex with men.Relationship between viral suppression,
prescription of antiretroviral therapy and sexual
risk behaviour
HIV-infected adults who were virally suppressed
were significantly less likely than those who were not
virally suppressed to engage in vaginal or anal sex
(prevalence ratio, 0.88; 95% CI, 0.82–0.93) and
unprotected vaginal or anal sex (prevalence ratio,
0.85; 95% CI, 0.73–0.98). Persons who were virally
suppressed were also less likely to engage in unprotected
vaginal or anal sex with a partner of negative or unknown
HIV status (prevalence ratio, 0.79; 95% CI, 0.64–0.99)
(Table 3). MSM who achieved viral suppression were
significantly less likely than MSM who were not virally
suppressed to engage in vaginal or anal sex (prevalence
ratio, 0.87; 95% CI, 0.80–0.96), unprotected vaginal
or anal sex (prevalence ratio, 0.78; 95% CI, 0.66–0.93),
and unprotected vaginal or anal sex with a partner
of negative or unknown HIV status (prevalence ratio,
0.76; 95% CI, 0.60–0.97). WSM who achieved viral
suppression were significantly less likely to engage in
vaginal or anal sex (prevalence ratio, 0.81; 95%CI, 0.71–
0.93), but viral suppression was not significantly
associated with unprotected vaginal or anal sex or
unprotected sex with a partner of negative or unknown
HIV status. There were no statistically significantCopyright © Lippincott Williams & Wilkins. Unautassociations between viral suppression and each of the
three measures of sexual risk behaviours for MSW.
To establish whether the association between viral
suppression and sexual risk behaviours was mediated by
ART use, we used a logistic regression model of persons
whowere virally suppressed, persons whowere prescribed
ARTbutwere not virally suppressed and personswhowere
not prescribedARTandwere not virally suppressed.Given
that most persons were prescribed ART, sample sizes were
too small for a separate model for each group; thus, we
present a single model. The model indicated that a
significantly higher percentage of persons who were not
prescribed ART, compared with persons prescribed ART
and suppressed and persons prescribed ART and not
suppressed, engaged in each of the three sexual risk
behaviours considered (Table 4). Thus, these models
suggest that ART use mediated the relationship between
viral suppression and sexual risk behaviours.Discussion
We found that the majority of HIV-infected adults
receiving care in the U.S. did not engage in sexual riskhorized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Una
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.uthobehaviours that have the potential to transmit HIV.
However, of the 12% of persons who engaged in
unprotected vaginal or anal sex with at least one partner
of negative or unknown HIV status, approximately
half did so while not virally suppressed. This analysis
provides the first nationally representative estimates
of sexual risk behaviour since the HIV Cost and
Utilization Study, which was conducted in 1996,
in the pre-ART era [3]. Our estimates – that 30% of
HIV-infected MSM engaged in unprotected vaginal
and anal sex and that 13% did so with a partner of
negative or unknown HIV status – are lower than
estimates from a recent meta-analysis indicating that
43% of HIV-infected MSM engaged in unprotected
anal sex and that 26% did so with a partner of unknown
or negative status [14]. However, a study that sampled
HIV-infected persons from clinics and community
organizations in four large U.S. cities found that
16% of MSM, 13% of MSW and 19% of WSM had
unprotected sex with partners of negative or unknown
HIV status, findings that are more consistent with our
estimates of 13, 9 and 15%, respectively [27].
Since ART became widely available, concerns have been
raised that the perceived reduction in sexual transmission
risk secondary to viral suppression might lead to increased
sexual risk behaviour. The 2012 recommendation by the
U.S. Department of Health and Human Services [28]
to provide ART regardless of CD4þ T-lymphocyte
count further emphasized the importance of under-
standing the relationship between viral suppression and
sexual risk behaviour. In the HIV Prevention Trials
Network (HPTN) 052 study [5], which demonstrated
that early initiation of ART reduces the likelihood
of heterosexual HIV-1 transmission, condom use was
extremely high among participants. However, condoms
and behavioural-risk reduction interventions were
provided to all participants; therefore, this level of
behavioural risk reduction may not be achieved in real-
world settings [10]. Most previous studies evaluating the
association between ARTuse and sexual risk behaviour in
the United States, among both MSM and heterosexual
men and women, have not found ART use to be
associated with increased sexual risk behaviour [12,14].
As our data are cross-sectional, wewere unable to evaluate
changes in risk behaviour before and after ART initiation.
However, we found no evidence that people receiving
ART were more likely to engage sexual risk behaviour
than those who were not. In fact, we found that persons
who were virally suppressed were less likely to engage
in vaginal or anal sex, unprotected vaginal or anal sex, and
unprotected vaginal or anal sex with a partner of negative
or unknown HIV status. Furthermore, those persons
who were prescribed ARTwere less likely to engage in
risk behaviours, regardless of viral suppression, which
suggests that ARTuse mediated the relationship between
viral suppression and sexual behaviours. This finding
may be a result of prevention interventions delivered inrized reproduction of this article is prohibited.
Sexual risk behaviour and viral suppression Mattson et al. 1209
Table 4. Weighted percentage of sexual risk behaviours and associations with viral suppressiona and antiretroviral therapy use among adults
with HIV diagnosis for at least 12 months and receiving medical care in the United States, Medical Monitoring Project, 2009.
Totalb
% (95% CI) PR (95% CI)
P for modified
Rao-Scott chi-square test
Vaginal/anal sex
Suppressed 52 (49–55) 0.78 (0.70–0.86) <0.01
Prescribed ART, not suppressed 58 (55–61) 0.87 (0.79–0.95) <0.01
Not prescribed ART, not suppressed 67 (62–72) Ref
Unprotected vaginal or anal sex
Suppressed 22 (19–25) 0.67 (0.52–0.85) <0.01
Prescribed ART, not suppressed 25 (21–29) 0.75 (0.62–0.91) <0.01
Not prescribed ART, not suppressed 33 (26–40) Ref
Unprotected vaginal or anal sex with a partner of negative or unknown HIV status
Suppressed 11 (9–13) 0.60 (0.42–0.85) 0.01
Prescribed ART, not suppressed 13 (11–16) 0.74 (0.56–0.98) 0.04
Not prescribed ART, not suppressed 18 (14–23) Ref
ART, antiretroviral therapy; CI, confidence interval; PR, prevalence ratio.
aNote: viral suppression is defined as all viral load measurements in the 12 months before interview undetectable or <200copies/ml.
bExcludes persons who reported no sexual behavior and did not report their sexual orientation as heterosexual, homosexual or bisexual. Includes
transgender participants (n¼64) andwomenwho have sex with women (n¼26) because sample sizes were too small to provide valid estimates for
separate analysis.the care setting, possible ART side effects that could
decrease libido (e.g. depression or anxiety) or an
indication that persons who are prescribed ART differ
from those who are not. Although our analysis was
not designed to address the causal relationship between
ART use, viral suppression and sexual risk behaviour,
it indicates that virally suppressed persons were less
likely to engage in risky sexual behaviours. In other
words, those individuals who were not virally
suppressed, and therefore at a greatest risk of transmitting
HIV [5], were also more likely to engage in sexual
behaviours that have the potential to transmit HIV.
This suggests that persons not on ART and not virally
suppressed may be in need of targeted prevention
interventions.
The association between viral suppression and sexual
behaviours was not statistically significant for all groups.
MSM who were virally suppressed were significantly less
likely to engage in all three measures of sexual risk
behaviour than HIV-infected MSM who were not
virally suppressed. For MSW and WSM, the trend was
the same in regard to vaginal or anal sex, but none of
the differences were statistically significant for MSW.
The only statistically significant association for WSMwas
engagement in vaginal or anal sex. Although this null
result could, in part, be explained by the smaller sample
size of these groups, our findings are consistent with those
of other studies that found no association between viral
suppression and risk behaviour [29,30].
Compared with MSW, MSM in our analysis were
more likely to report high-risk sexual behaviour, which is
consistent with previous studies [3,29,31]. This increased
prevalence of risk behaviours, combined with the
increased per-act transmissibility of HIV through analCopyright © Lippincott Williams & Wilkins. Unautintercourse (both insertive and receptive) [31], highlights
the pressing need for effective prevention efforts for
MSM. Implementation of prevention efforts will require
careful consideration of biological, network, social
and structural factors (e.g. stigma, discrimination and
homophobia) among MSM [32].
Combination prevention approaches, including beha-
vioural risk reduction counselling, and access to ART
and medical care should be available to all HIV-infected
adults to maximize the individual and public health
benefit. However, recent data on the HIV care
continuum indicate that additional work is needed at
every step in the continuum: expanded HIV testing,
increased numbers of HIV-infected adults linked to and
retained in care, and increased numbers of persons who
are prescribed ART and ultimately achieve viral
suppression [33]. The fact that only 25% of HIV-infected
persons in the United States are virally suppressed
highlights the need for action [34]. In addition, the
delivery of behavioural risk reduction interventions in
the clinical setting is essential. Medical visits provide an
opportunity to discuss risk behaviours, reinforce pre-
vention messages, diagnose and treat STIs, and emphasize
medication adherence. Effective evidence-based inter-
ventions that can be delivered by providers as brief
messages during clinic visits are available [35], but too few
providers discuss HIV prevention with their patients
[33]. STI screening and treatment, when indicated, is
recommended by guidelines and is likely to reduce HIV
transmission [36], but data indicate that too few patients
are being screened by their providers [37]. Combination
prevention approaches will require additional efforts
to engage and retain HIV-infected persons in care and
improve the delivery of risk reduction interventions
in clinical settings.horized reproduction of this article is prohibited.
Co
1210 AIDS 2014, Vol 28 No 8Our analysis has limitations. First, MMP data reflect the
experiences of HIV-infected adults receiving medical
care in the United States; thus, our results cannot be
generalized to persons unaware of their HIV infection or
to those not receiving medical care. Sexual behaviours
and viral suppression status are likely to differ among
persons in care and persons not in care [38]. Also, we did
not collect information on whether persons were aware
of their current viral load status, which could influence
subsequent risk behaviour. In addition, given less than
optimal response rates, nonresponse bias is possible.
Furthermore, because compliant patients may have been
more likely to participate in MMP, it is possible that
results may differ for less compliant patients. However,
we collected information on sampled patients (sex, age,
race, length of time since diagnosis) and facilities
(HIV patient case load) and were able to compare the
characteristics of respondents and nonrespondents. Our
estimates were then weighted to minimize nonresponse
bias. In addition, our probabilistic sampling frame was
rigorously constructed, geographically diverse, included
both urban and rural clinics, public and private facilities,
providers who see many and few HIV-infected patients
and jurisdictions that have high, medium and low HIV
prevalence. Furthermore, empirical research indicates
that low response rates are not necessarily indicative of
nonresponse bias, particularly when probabilistic samples
are drawn from rigorously constructed frames [39].
Next, because this is a cross-sectional analysis and we
did not collect dates for the sexual behaviour data
(beyond knowing they occurred in the 12 months
before the interview), we cannot determine the exact
timing of sexual risk behaviour with respect to viral
suppression. Finally, sexual risk behaviour data were
collected during face-to-face interviews, so social
desirability bias may have led to underreporting of some
behaviours [40].
Conclusion
Of an estimated 408 092 HIV-infected adults receiving
medical care in the United States, the majority of
persons did not engage in sexual risk behaviours that have
the potential to transmit HIV. Of the 12% of persons who
engaged in unprotected vaginal or anal sex with a partner
of unknown or negative HIV status, approximately half
were not virally suppressed, which highlights an unmet
need for effective prevention interventions. We found no
evidence that people on ARTengaged in higher levels of
sexual risk behaviour than those who were not. In fact,
persons on ART and virally suppressed were less likely
than those not on ART to engage in sexual risk
behaviours. Behavioural risk reduction will continue to
be a necessary component of HIV prevention efforts;
clinicians play a vital role in HIV prevention and
should use medical visits to discuss sexual risk beha-
viour, reinforce prevention messages, diagnose and treat
STIs, and emphasize medication adherence.pyright © Lippincott Williams & Wilkins. UnauthoAcknowledgements
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